Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors

On this page
Share

Protein tyrosine phosphatase 1B (PTP1B) has been considered as a promising therapeutic target for type 2 diabetes mellitus (T2DM) and obesity due to its key regulating effects in insulin signaling and leptin receptor pathways. In this work, a series of cis- and trans-pyrrolidine bisarylethenesulfonic acid esters were prepared and their PTP1B inhibitory potency, selectivity and membrane permeability were evaluated. These novel stereoisomeric molecules especially trans-isomers exhibited remarkable inhibitory activity, significant selectivity as well as good membrane permeability (e.g. compound 28a, IC50 = 120, 1940 and 2670 nM against PTP1B, TCPTP and SHP2 respectively, and P app = 1.74 × 10 -6 cm/s). Molecular simulations indicated that trans-pyrrolidine bisarylethenesulfonic acid esters yielded the stronger binding affinity than their cis-isomers by constructing more interactions with non-catalytic sites of PTP1B. Further biological activity studies revealed that compound 28a could enhance insulin-stimulated glucose uptake and insulin-mediated insulin receptor β (IRβ) phosphorylation with no significant cytotoxicity.

Explore other resources

Case Studies

See how programs moved from early target work to IND. Real timelines, real decisions, and the science that got partners there.

Resource Library

Peer-reviewed publications, press releases, and interviews with our scientists. More than 20 years of discovery, in one place.

Insights

Perspectives from the people running programs every day, plus news on the partnerships and capabilities shaping the work.

Events

Webinars, conferences, and workshops throughout the year. Find out where our teams will be and what they’ll be presenting.

START YOUR JOURNEY
Phase
Modality
Therapeutic Area